Open AccessThree ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients
Author(s) -
Kanasaki Keizo,
Konishi Kazunori,
Hayashi Ranji,
Shiroeda Hisakazu,
Nomura Tomoe,
Nakagawa Atsushi,
Nagai Takako,
TakedaWatanabe Ai,
Ito Hiroki,
Tsuda Shinichi,
Kitada Munehiro,
Fujii Mizue,
Kanasaki Megumi,
Nishizawa Makoto,
Nakano Yasuharu,
Tomita Yasuto,
Ueda Nobuhiko,
Kosaka Takeo,
Koya Daisuke
Publication year - 2013
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12095
Subject(s) - medicine , incretin , ileus , dipeptidyl peptidase 4 , diabetes mellitus , dipeptidyl peptidase , blood sugar , adverse effect , glucagon like peptide 1 , pharmacology , gastroenterology , endocrinology , type 2 diabetes , enzyme , biochemistry , chemistry
Dipeptidyl peptidase ( DPP )‐4 inhibitors are a new class of antidiabetic drugs that increase incretin hormone levels to enhance blood sugar level‐dependent insulinotropic effects, suppress glucagon action, and reduce bowel motility. These incretin effects are ideal for blood sugar control. However, the safety profile of DPP ‐4 inhibitors is not yet established. Herein, we present three cases of ileus, considered to be closely related to the use of DPP ‐4 inhibitors, in diabetic patients. Each of the three patients exhibited some risk of a deficiency in bowel movement; the onset of ileus was within 40 days after strengthened inhibition of DPP ‐4. The use of a DPP ‐4 inhibitor could be safe, although the cases presented herein enable us to inform the scientific community to some of the potential adverse effects of the use of DPP ‐4 inhibitors in select populations.